These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38174291)

  • 1. Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study.
    Niles SE; Blazy P; Cheuvront SN; Kenefick RW; Vidyasagar S; Smith AB; Fawkes N; Denman W
    World J Gastrointest Pharmacol Ther; 2023 Dec; 14(5):39-49. PubMed ID: 38174291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K; Wolzt M; Moser G; Keip B; Peter J; Meisslitzer C; Gouya G; Freissmuth M; Tschegg C
    World J Gastroenterol; 2022 Dec; 28(46):6573-6588. PubMed ID: 36569277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and dose response of
    Martoni CJ; Srivastava S; Damholt A; Leyer GJ
    World J Gastroenterol; 2023 Jul; 29(28):4451-4465. PubMed ID: 37576702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
    Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
    Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live
    Srivastava S; Basak U; Naghibi M; Vijayakumar V; Parihar R; Patel J; Jadon PS; Pandit A; Dargad RR; Khanna S; Kumar S; Day R
    Gut Microbes; 2024; 16(1):2338322. PubMed ID: 38630015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D.
    Eswaran SL; Chey WD; Han-Markey T; Ball S; Jackson K
    Am J Gastroenterol; 2016 Dec; 111(12):1824-1832. PubMed ID: 27725652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points.
    Lacy BE; Chang L; Rao SSC; Heimanson Z; Sayuk GS
    Clin Ther; 2023 Mar; 45(3):198-209. PubMed ID: 36922331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.
    Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
    Biopsychosoc Med; 2017; 11():8. PubMed ID: 28331539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.
    Khalilian A; Ahmadimoghaddam D; Saki S; Mohammadi Y; Mehrpooya M
    Biopsychosoc Med; 2021 Feb; 15(1):3. PubMed ID: 33536043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial.
    Zheng Y; Ching J; Cheng CW; Lam WC; Chan KL; Zhang X; Lam PY; Wu XY; Zhong LLD; Cao PH; Lo CW; Cheong PK; Lin Z; Koh M; Wu J; Bian ZX
    Chin Med; 2021 Nov; 16(1):117. PubMed ID: 34774080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.
    Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
    Biopsychosoc Med; 2017; 11():7. PubMed ID: 28293280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effectiveness of Synbiotic Preparation Containing
    Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kosikowski W; Szczerbiński M; Gantzel J; Cukrowska B
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32635661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: A randomized crossover trial.
    Algera JP; Demir D; Törnblom H; Nybacka S; Simrén M; Störsrud S
    Clin Nutr; 2022 Dec; 41(12):2792-2800. PubMed ID: 36384081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.
    Holvoet T; Joossens M; Vázquez-Castellanos JF; Christiaens E; Heyerick L; Boelens J; Verhasselt B; van Vlierberghe H; De Vos M; Raes J; De Looze D
    Gastroenterology; 2021 Jan; 160(1):145-157.e8. PubMed ID: 32681922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.